Search

Your search keyword '"Csanádi, Marcell"' showing total 201 results
Start Over Author "Csanádi, Marcell"
201 results on '"Csanádi, Marcell"'

8. Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania

Author

Lorenzovici László, Székely Andrea, Farkas-Ráduly Szabolcs, Jitaru Ciprian, and Csanádi Marcell

Subjects
heart failure, iron deficiency, treatment cost, budget impact, ferric carboxymaltose, romania, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Background: Ferric carboxymaltose (FCM) treatment in case of iron deficient (ID) patients with chronic heart failure (CHF) has shown great promise according to the findings of recent studies in improvement of symptoms and quality of life, New York Heart Association (NYHA) classification, and exercise capacity.

Published
2019
Full Text
View/download PDF

20. Improved survival of non-small cell lung cancer patients after introducing patient navigation: A retrospective cohort study with propensity score weighted historic control

Author

Pitter, János G., primary, Moizs, Mariann, additional, Ezer, Éva Somogyiné, additional, Lukács, Gábor, additional, Szigeti, Annamária, additional, Repa, Imre, additional, Csanádi, Marcell, additional, Rutten-van Mölken, Maureen P. M. H., additional, Islam, Kamrul, additional, Kaló, Zoltán, additional, and Vokó, Zoltán, additional

Published
2022
Full Text
View/download PDF

24. Improved survival of non-small cell lung cancer patients after introducing patient navigation:A retrospective cohort study with propensity score weighted historic control

Author

Pitter, János G., Moizs, Mariann, Ezer, Éva Somogyiné, Lukács, Gábor, Szigeti, Annamária, Repa, Imre, Csanádi, Marcell, Rutten-van Mölken, Maureen P.M.H., Islam, Kamrul, Kaló, Zoltán, Vokó, Zoltán, Pitter, János G., Moizs, Mariann, Ezer, Éva Somogyiné, Lukács, Gábor, Szigeti, Annamária, Repa, Imre, Csanádi, Marcell, Rutten-van Mölken, Maureen P.M.H., Islam, Kamrul, Kaló, Zoltán, and Vokó, Zoltán

Abstract

OnkoNetwork is a patient navigation program established in the Moritz Kaposi General Hospital to improve the timeliness and completeness of cancer investigations and treatment. The H2020 SELFIE consortium selected OnkoNetwork as a promising integrated care initiative in Hungary and conducted a multicriteria decision analysis based on health, patient experience, and cost outcomes. In this paper, a more detailed analysis of clinical impacts is provided in the largest subgroup, non-small cell lung cancer (NSCLC) patients. A retrospective cohort study was conducted, enrolling new cancer suspect patients with subsequently confirmed NSCLC in two annual periods, before and after OnkoNetwork implementation (control and intervention cohorts, respectively). To control for selection bias and confounding, baseline balance was improved via propensity score weighting. Overall survival was analyzed in univariate and multivariate weighted Cox regression models and the effect was further characterized in a counterfactual analysis. Our analysis included 123 intervention and 173 control NSCLC patients from early to advanced stage, with significant between-cohort baseline differences. The propensity score-based weighting resulted in good baseline balance. A large survival benefit was observed in the intervention cohort, and intervention was an independent predictor of longer survival in a multivariate analysis when all baseline characteristics were included (HR = 0.63, p = 0.039). When post-baseline variables were included in the model, belonging to the intervention cohort was not an independent predictor of survival, but the survival benefit was explained by slightly better stage distribution and ECOG status at treatment initiation, together with trends for broader use of PET-CT and higher resectability rate. In conclusion, patient navigation is a valuable tool to improve cancer outcomes by facilitating more timely and complete cancer diagnostics. Contradictory evidence in the lite

Published
2022

26. Burden of Chronic Heart Failure in Romania

Author

Lorenzovici, László, primary, Bârzan-Székely, Andrea, additional, Farkas-Ráduly, Szabolcs, additional, Pană, Bogdan C., additional, Csanádi, Marcell, additional, Chiriac, Nona Delia, additional, and Kaló, Zoltán, additional

Published
2022
Full Text
View/download PDF

28. Benefits Of Timely Care In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence

Author

Lukács, Gábor, Kovács, Árpád, Csanádi, Marcell, Moizs, Mariann, Repa, Imre, Kaló, Zoltán, Vokó, Zoltán, and Pitter, János György

Subjects
wait time, bias, systematic review, delay, pancreatic cancer, Review, prognosis
Abstract

The evidence base of policies that improve the timeliness of cancer care is under ongoing debate. Pancreatic cancer is frequently diagnosed in a stage when curative therapy is not feasible; hence, it is an important target for timelier healthcare interventions. The objectives of our research were to identify all clinical studies on pancreatic cancer care delays via a systematic literature review, to assess the study methodologies for possible biases, to conclude on the available evidence, and to formulate research recommendations on evidence gaps. Nineteen studies were identified and eight reported multivariate analyses. Although many sources of bias shifted the results towards negative or paradoxical findings, a statistically significant association of shorter delays with better clinical outcomes was demonstrated in the majority of studies reporting multivariate analyses. Noninferiority analyses were not published. Further efforts to provide timely care for pancreatic cancer patients are encouraged, and studies on the associations of delay with patient experience and healthcare resource utilization are warranted.

Published
2019

30. sj-doc-1-mpp-10.1177_2381468320984974 – Supplemental material for Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe

Author

Gini, Andrea, Buskermolen, Maaike, Senore, Carlo, Anttila, Ahti, Mlakar, Dominika Novak, Veerus, Piret, Csanádi, Marcell, Jansen, Erik E. L., Zielonke, Nadine, Heinävaara, Sirpa, Széles, György, Segnan, Nereo, Koning, Harry J. De, and Lansdorp-Vogelaar, Iris

Subjects
111799 Public Health and Health Services not elsewhere classified, FOS: Health sciences
Abstract

Supplemental material, sj-doc-1-mpp-10.1177_2381468320984974 for Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe by Andrea Gini, Maaike Buskermolen, Carlo Senore, Ahti Anttila, Dominika Novak Mlakar, Piret Veerus, Marcell Csanádi, Erik E. L. Jansen, Nadine Zielonke, Sirpa Heinävaara, György Széles, Nereo Segnan, Harry J. de Koning and Iris Lansdorp-Vogelaar in MDM Policy & Practice

Published
2021
Full Text
View/download PDF

31. The EU-TOPIA evaluation tool:An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe

Author

Gini, Andrea, van Ravesteyn, Nicolien T., Jansen, Erik E.L., Heijnsdijk, Eveline A.M., Senore, Carlo, Anttila, Ahti, Novak Mlakar, Dominika, Veerus, Piret, Csanádi, Marcell, Zielonke, Nadine, Heinävaara, Sirpa, Széles, György, Segnan, Nereo, de Koning, Harry J., Lansdorp-Vogelaar, Iris, Gini, Andrea, van Ravesteyn, Nicolien T., Jansen, Erik E.L., Heijnsdijk, Eveline A.M., Senore, Carlo, Anttila, Ahti, Novak Mlakar, Dominika, Veerus, Piret, Csanádi, Marcell, Zielonke, Nadine, Heinävaara, Sirpa, Széles, György, Segnan, Nereo, de Koning, Harry J., and Lansdorp-Vogelaar, Iris

Abstract

Background: Aiming to support European countries in improving their breast, cervical, and colorectal cancer (CRC) screening programmes, the EU-TOPIA consortium has developed an online user-friendly tool (the EU-TOPIA evaluation tool; https://miscan.eu-topia.org) based on the Microsimulation Screening Analysis (MISCAN) model. Methods: We designed an online platform that allows stakeholders to use their country-specific data (demographic, epidemiological, and cancer screening information) to quantify future harms and benefits of different cancer screening scenarios in their country. Current cancer screening programmes and impacts of potential changes in screening protocols (such as extending target ages or increasing screening attendance) can be simulated. Results are scaled to the country-specific population. To illustrate the tool, we used the tool to simulate two different CRC screening scenarios in the Netherlands: biennial fecal immunochemical testing (FIT) in ages 55–75 and colonoscopy every ten years in ages 55–75. Data from the Dutch screening programme was used to inform both scenarios. Results: A total of 482,700 CRC cases and 178,000 CRC deaths were estimated in the Netherlands with FIT screening (for individuals aged 40–100 years, 2018–2050), with 47.3 million FITs performed (1.92 million positives of which 1.64 million adhered to diagnostic colonoscopy). With colonoscopy screening, CRC incidence and mortality were, respectively, up to 17% and 14% lower than in the current FIT screening programme, requiring, however, a colonoscopy demand that was 7-fold higher. Conclusions: Our study presents an essential online tool for stakeholders and medical societies to quantify estimates of benefits and harms of early cancer detection in Europe.

Published
2021

32. Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe

Author

Gini, Andrea, primary, Buskermolen, Maaike, additional, Senore, Carlo, additional, Anttila, Ahti, additional, Novak Mlakar, Dominika, additional, Veerus, Piret, additional, Csanádi, Marcell, additional, Jansen, Erik E. L., additional, Zielonke, Nadine, additional, Heinävaara, Sirpa, additional, Széles, György, additional, Segnan, Nereo, additional, de Koning, Harry J., additional, and Lansdorp-Vogelaar, Iris, additional

Published
2021
Full Text
View/download PDF

34. Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary

Author

Csanádi, Marcell, primary, Gini, Andrea, additional, Koning, Harry de, additional, Széles, György, additional, Pitter, János G, additional, Oroszi, Beatrix, additional, Pataki, Piroska, additional, Fadgyas-Freyler, Petra, additional, Korponai, Gyula, additional, Vokó, Zoltán, additional, and Lansdorp-Vogelaar, Iris, additional

Published
2020
Full Text
View/download PDF

38. Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review

Author

Gini, Andrea, primary, Jansen, Erik E.L., additional, Zielonke, Nadine, additional, Meester, Reinier G.S., additional, Senore, Carlo, additional, Anttila, Ahti, additional, Segnan, Nereo, additional, Mlakar, Dominika Novak, additional, de Koning, Harry J., additional, Lansdorp-Vogelaar, Iris, additional, Veerus, Piret, additional, Heinävaara, Sirpa, additional, Sarkeala, Tytti, additional, Csanádi, Marcell, additional, Pitter, Janos, additional, Széles, György, additional, Vokó, Zoltán, additional, Minozzi, Silvia, additional, van Ballegooijen, Marjolein, additional, Driesprong - de Kok, Inge, additional, Gini, Andrea, additional, Heijnsdijk, Eveline, additional, Jansen, Erik, additional, de Koning, Harry, additional, Lansdorp – Vogelaar, Iris, additional, van Ravesteyn, Nicolien, additional, Ivanus, Urska, additional, Jarm, Katja, additional, Primic-Žakelj, Maja, additional, McKee, Martin, additional, and Priaulx, Jennifer, additional

Published
2020
Full Text
View/download PDF

39. Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review

Author

Jansen, Erik E.L., primary, Zielonke, Nadine, additional, Gini, Andrea, additional, Anttila, Ahti, additional, Segnan, Nereo, additional, Vokó, Zoltán, additional, Ivanuš, Urška, additional, McKee, Martin, additional, de Koning, Harry J., additional, de Kok, Inge M.C.M., additional, Veerus, Piret, additional, Heinävaara, Sirpa, additional, Sarkeala, Tytti, additional, Csanádi, Marcell, additional, Pitter, Janos, additional, Széles, György, additional, Minozzi, Silvia, additional, Senore, Carlo, additional, van Ballegooijen, Marjolein, additional, Driesprong - de Kok, Inge, additional, Heijnsdijk, Eveline, additional, Jansen, Erik, additional, de Koning, Harry, additional, Lansdorp – Vogelaar, Iris, additional, van Ravesteyn, Nicolien, additional, Ivanus, Urska, additional, Jarm, Katja, additional, Mlakar, Dominika Novak, additional, Primic-Žakelj, Maja, additional, and Priaulx, Jennifer, additional

Published
2020
Full Text
View/download PDF

42. Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary.

Author

Csanádi, Marcell, Gini, Andrea, Koning, Harry de, Széles, György, Pitter, János G, Oroszi, Beatrix, Pataki, Piroska, Fadgyas-Freyler, Petra, Korponai, Gyula, Vokó, Zoltán, and Lansdorp-Vogelaar, Iris

Subjects
*FECAL analysis, *ECONOMICS, *NATIONAL health services, *COLONOSCOPY, *EARLY detection of cancer, *COLORECTAL cancer, *HUMAN services programs, *MEDICAL care use, *COST effectiveness, *COST analysis, *STATISTICAL models, *HEALTH care rationing
Abstract

Objective: The national population-based colorectal cancer screening programme in Hungary was initiated in December 2018. We aimed to evaluate the current programme and investigate the costs and benefits of potential future changes to overcome the low coverage of the target population. Methods: We performed an economic evaluation from a healthcare payer perspective using an established micro-simulation model (Microsimulation Screening Analysis-Colon). We simulated costs and benefits of screening with fecal immunochemical test in the Hungarian population aged 50–100, investigating also the impact of potential future scenarios which were assumed to increase invitation coverage: improvement of the IT platform currently used by GPs or distributing the tests through pharmacies instead of GPs. Results: The model predicted that the current screening programme could lead to 6.2% colorectal cancer mortality reduction between 2018 and 2050 compared to no screening. Even higher reductions, up to 16.6%, were estimated when tests were distributed through pharmacies and higher coverage was assumed. This change in the programme was estimated to require up to 26 million performed fecal immunochemical tests and 1 million colonoscopies for the simulated period. These future scenarios have acceptable cost-benefit ratios of €8000–€8700 per life-years gained depending on the assumed adherence of invited individuals. Conclusions: With its limitations, the current colorectal cancer screening programme in Hungary will have a modest impact on colorectal cancer mortality. Significant improvements in mortality reduction could be made at acceptable costs, if the tests were to be distributed by pharmacies allowing the entire target population to be invited. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. Key indicators of organized cancer screening programs: Results from a Delphi study

Author

Csanádi, Marcell, primary, de Kok, Inge MCM, additional, Heijnsdijk, Eveline AM, additional, Anttila, Ahti, additional, Heinävaara, Sirpa, additional, Pitter, János G, additional, Széles, György, additional, Ivanuš, Urška, additional, Priaulx, Jennifer, additional, Veerus, Piret, additional, Senore, Carlo, additional, Koning, Harry J de, additional, and Vokó, Zoltán, additional

Published
2019
Full Text
View/download PDF

49. Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary.

Author

Harsányi, András, Csanádi, Marcell, Márky, Kristóf, Vincziczki, Áron Zoltán, Kaló, Zoltán, and Inotai, András

Abstract

Objectives: Utilization of multisource biological (off-patent originator and its biosimilar) medicines can improve the efficiency of resource allocation by 1) generating savings while maintaining health outcomes or 2) increasing the number of patients treated with more affordable treatments. This study evaluates the efficiency of the Hungarian biosimilar drug policy on the case of biosimilar infliximab. Methods: We analyzed the utilization of biologicals in all reimbursed indications of infliximab including initial therapy of new patients and switching patterns retrospectively based on patient-level payer's data between September 2012 and December 2016. Results: Despite the economic rationale, patent expiry did not manifest in increased utilization of multisource infliximab in an access-restricted environment: 1) Patients previously treated with original biologicals were switched mainly to other original biologicals instead of more affordable biosimilar alternatives. 2) Although some treatment-naive patients started on more affordable multisource infliximab with price competition, the majority of new patients started on other original biologicals with monopolistic price. Conclusion: Policy tools and measures should be developed to facilitate first-line use of multisource biologicals for treatment-naive patients and promoting the use of more affordable multisource biologicals in case of switching. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results